Get To Know Us

Paul Westberg, MBA

Paul Westberg, MBA

Strategic Advisor

Paul Westberg is a strategic business executive with more than 25 years of broad transactions, financing, market planning, and advisory experience focused on advancing transformational therapies in the life sciences sector. He was most recently the Chief Business Officer of Qpex Biopharma, a resistance-focused infectious disease company, which was acquired by Shionogi. Earlier in his career, Mr. Westberg was Chief Business Officer at Versartis and has previously served in numerous business development and finance roles for start-up companies since starting his career at Genentech. Mr. Westberg received his MBA from the University of California, Berkeley and his BA from the University of California, San Diego.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.